Mirador Therapeutics, Inc.

About Mirador Therapeutics, Inc.

Mirador Therapeutics is focused on advancing precision medicine for immune-mediated inflammatory and fibrotic diseases. They aim to break through efficacy limitations in current treatments by using a science-driven, precision-first approach to discover and develop first-in-class and best-in-class therapies, ultimately improving patient lives.

Products & Services

Mirador360™:An end-to-end precision discovery and development engine that uses cutting-edge biology, multi-modal data, AI, and advanced analytics to identify novel targets, select combination therapies, and pinpoint patients likely to benefit from treatments for immuno-fibrotic diseases.

Pipeline of Transformational Therapies:A pipeline of potentially transformational therapies targeting immuno-fibrotic diseases, developed through the Mirador360™ platform.

Specialties

Precision Medicine Immune-mediated Inflammatory Diseases Fibrotic Diseases AI and Advanced Analytics Immuno-fibrotic Therapies

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 250000000 MR: - FA: $250 million FAN: 250000000	D: 2026-01-12 FD: 2026-01-12	17 investors

Series B Latest

2026-01-12

$250.0M

17 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Mark C. McKenna

Founder, Chairman & CEO

O

Olivier Laurent, Ph.D.

Chief Scientific Officer

A

Allison Luo

Chief Medical Officer

W

William Sandborn, M.D.

Chief Strategy Officer

T

Tim Andrews

Chief Legal Officer

V

Vika Brough

Chief Accounting Officer

View 12 more team members with Pro

Unlock Full Team Directory

Recent News